MCTA MCTA
Company Profile ↓Company Overview
MCTA (MCTA) is a publicly traded company listed on with a market capitalization of $497.30M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 10.8% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.18.
Recent Developments
- Mar 2026 Revenue of $4.81M (-22.7% YoY); net profit $-22.65K.
- Trailing 12 Months Year-on-year growth — revenue -22.7%, earnings -101.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.84% |
| 1 Year: | -22.73% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -101.89% |
Stock Price Performance
| 1 Year: | +319.36% |
| 6 Months: | +0.00% |
| 3 Months: | +0.00% |
| 1 Month: | +0.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)68.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.8% over 5 years.
CONS
- Trading at a high P/E of 414.7.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 3.53M | 6.02M | 6.22M | 4.81M |
| Cost of Revenue | 2.04M | 2.10M | 2.04M | 1.80M |
| Gross Profit | 1.49M | 3.91M | 4.18M | 3.01M |
| Operating Expenses | 1.78M | 2.74M | 2.57M | 2.88M |
| Operating Income | -287.50K | 1.17M | 1.62M | 128.87K |
| EBITDA | -189.13K | 1.42M | 1.72M | 365.34K |
| Interest Expense | 20.26K | 26.05K | 20.87K | 15.80K |
| Pretax Income | -420.47K | 1.00M | 1.44M | 133.47K |
| Tax Provision | -84.86K | 181.75K | 236.08K | 156.11K |
| Net Income | -305.12K | 777.81K | 1.20M | -22.65K |
| Diluted EPS | -0.02 | 0.05 | 0.07 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 6.38M | 4.88M | 5.36M | 9.87M |
| Current Assets | 4.12M | 3.67M | 3.37M | 8.17M |
| Cash & Equivalents | 1.93M | 2.10M | 816.77K | 4.70M |
| Inventory | 66.33K | 28.15K | 26.80K | 25.62K |
| Receivables | 186.64K | 351.61K | 395.90K | 201.48K |
| Total Liabilities | 7.65M | 6.03M | 5.31M | 4.69M |
| Current Liabilities | 7.17M | 5.88M | 4.95M | 4.33M |
| Long Term Debt | - | - | - | - |
| Total Debt | 1.81M | 961.38K | 1.16M | 908.02K |
| Total Equity | -1.16M | -1.08M | 49.24K | 5.18M |
| Shares Outstanding | 16.94M | 16.94M | 16.94M | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | 2.43M | 295.43K | 425.89K | -1.22M |
| Investing Cash Flow | -606.19K | -210.60K | -2.23M | -179.01K |
| Financing Cash Flow | -1.43M | 100.14K | 521.30K | 5.29M |
| Capital Expenditure | -606.19K | -210.60K | -287.53K | -339.56K |
| Free Cash Flow | 1.83M | 84.83K | 138.36K | -1.56M |
| Net Change in Cash | 397.33K | 184.98K | -1.28M | 3.90M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 42.3% | 65.1% | 67.2% | 62.6% |
| Operating Margin % | -8.1% | 19.5% | 26.0% | 2.7% |
| Net Margin % | -8.6% | 12.9% | 19.3% | -0.5% |
| ROE % | 26.3% | -72.1% | 2,435.0% | -0.4% |
| ROCE % | 36.6% | -117.7% | 396.6% | 2.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MCTA
Middlefield Canadian Income PCC Rights Rollover Option Class A Revenue Breakdown – LSE:MCTA - TradingView
<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE5ucm52endHRHM1VkExT29ZRWdxaGVhZ1BJcHkyWHE1YlFpMjR4SGYyTEdDcDc4VDNUOW9sZS1ES2gxYklZY09OZmdUNnkxcThhLW9nSkdYY0JuMkNKNGx5Sml6MGh3QWw1R3dsTjJlMkxmN3c?oc=5" target="_blank">Middlefield …
Charming Medical Limited (MCTA) stock price, news, quote and history - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE15bk5HdnpiQkVXVEZXQ1V2azBoWE9jZXFIbndCQ1RGVmVqUDNMV0k2R3VHbVJuR2VSNWJGdmYzOWk2WUxpaURFN2Z2QlhLNE1ZZEE?oc=5" target="_blank">Charming Medical Limited (MCTA) stock price, news, quote…
CHARMING MEDICAL CLASS ACTION DEADLINE: Bragar Eagel & - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi0AJBVV95cUxPQXFKcnJucUtQNjYxOWRQbmdCVnhFdXlVRFkzSDNuOWljRzNnSG9MUTRqRURUU01EcE1pTzhyU21qY0RScXpNbGNNYjlpc1VvdllrOXNHNnVIc2RnNlRid0hIM1JwLU5YMXJpdDQzQUY3Qm1IczNuY3lMcTFYWUpFblpFSWZtbFl5V0JzbU…
Charming Medical Ord Shs Class A (MCTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9ZNE1TMFdrR01STER2NWwwWWhGQlJvNF9aZlF0TkRqU1E5cUZSTTNkS0dibmM4RmVEREwtaWJfMlRRY0ZLNGRxUjFYNkdvTkI4dThuMnYyQ3FsNU1CR2Q0M1FVSlFLWmtURUtVZTBR?oc=5" target="_blank">Charming Medical Or…
Nasdaq halts trading of Charming Medical after SEC suspension - Investing.com
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOS3hXSllUbGk3NDRLSHBjelI3ejlqQ20td2h3RnhWVFlWeHhhMWRfdV9uLVhKUnotckVFdDJ6T1R1LW1uVUUyNkRjQkV1RVBabE9zTU1ub1U0TzMtcmktbk44ZjBoUnpkYkZTbEZud0hLSVNraUxJVHk5VnhBa3ZtWmpMVlZyY3FmNW56c2…
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Charming Medical Limited (NASDAQ: MCTA) - Business Wire
<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxOWm5qNEpCTW5YLTh2NkdrdjJJSG1ZOUlNMjE4WHJZOFQ2MHMzQ1JjR0doVlhQSkVMOU9GX0F0VXg5MDdIUXo2clNxc3AzV0NVVUVOMEFuYWdNTmxZRDZHZWFEV0dUS242MlM4MGZZeXBGazlRX0NMVUxjaGlOb2dId0pkT01YZDNGTktOX2…
MCTA — Frequently Asked Questions
What is the current share price of MCTA?
As of 2026-08-05 17:25 PDT, MCTA trades at $29.36 on NASDAQ/NYSE. Its 52-week range is $6.20 to $29.36.
What is the market capitalisation of MCTA?
MCTA has a market capitalisation of $497.30M on NASDAQ/NYSE.
What is the P/E ratio of MCTA?
MCTA trades at a trailing price-to-earnings (P/E) ratio of 414.73. Its price-to-book (P/B) ratio is 95.98.
What is the return on equity (ROE) of MCTA?
MCTA has a return on equity (ROE) of -0.44%. Its return on capital employed (ROCE) is 2.33%.
Is MCTA a good stock to buy?
This page provides a data-driven analysis of MCTA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.